Monthly
Flexible month-to-month sexual health care.
- Flibanserin prescription review
- Licensed clinician oversight
- Care-team messaging
- Discreet pharmacy fulfillment
We understand that a healthy sex drive is an important part of overall well-being and intimate relationships. When sexual desire diminishes, it can affect confidence, emotional connection, and quality of life. Flibanserin Therapy offers a clinically proven, physician-guided solution for women experiencing Hypoactive Sexual Desire Disorder (HSDD).
Flibanserin is a non-hormonal, FDA-approved medication designed to enhance sexual desire by balancing key neurotransmitters in the brain. Unlike hormone-based therapies, it works centrally to increase dopamine and norepinephrine while decreasing serotonin, helping to restore natural sexual interest over time.
Flibanserin (Addyi)
A non-hormonal, once-daily prescription for adult women with acquired, generalized hypoactive sexual desire disorder. We review your history and medications before any prescription is issued.
How it works
From online intake to clinician review and discreet prescription fulfillment when appropriate.
Tell us about your symptoms, history, current medications, and any contributing factors you have noticed.
A licensed clinician reviews your intake to determine whether flibanserin fits your case and rules out interacting medications and contraindications.
If prescribed, your medication is fulfilled through licensed pharmacy partners and shipped discreetly.
Your care team checks response and tolerability around the 8-week mark and reviews whether to continue or change the plan.
Pricing
Your online visit, clinician review, prescription management, and care-team support in one program.
Flexible month-to-month sexual health care.
Save ~7% vs monthly
Aligned with the 8-week response window.
Save ~14% vs monthly
Our lowest monthly rate for ongoing care.
Medication, dosing, and pharmacy availability are determined by clinician review and may vary. Prescriptions are issued only when medically appropriate.
Eligibility
What is flibanserin?
Flibanserin (brand name Addyi) was approved by the FDA in 2015 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in adult women. It was the first medication specifically approved for low sexual desire in women. Unlike hormonal options, flibanserin acts on neurotransmitter systems in the brain — it is a multifunctional serotonin agonist and antagonist that is thought to balance the activity of serotonin, dopamine, and norepinephrine pathways involved in sexual response.
Flibanserin is taken as one 100 mg tablet at bedtime. It is intended for ongoing daily use rather than on-demand dosing. The FDA labeling recommends reviewing response after about eight weeks and discontinuing if a meaningful improvement is not seen. The medication carries specific cautions around alcohol use, hepatic impairment, and interactions with certain medications, so a clinician reviews these in detail before prescribing.
Patient experience
"The intake actually treated low desire as a real condition, and the clinician was thorough about my other medications."
"Discreet shipping and clear instructions. My care team was responsive when I had questions about side effects in the first week."
"The 8-week check-in was useful. We talked through what was working and what to adjust."
FAQ
No. Flibanserin is a non-hormonal medication that acts on serotonin, dopamine, and norepinephrine pathways in the brain. It is unrelated to estrogen, progesterone, or testosterone.
Flibanserin is taken daily and assessed over time. FDA labeling recommends reviewing response at around 8 weeks and discontinuing if you have not seen meaningful improvement.
Alcohol can increase the risk of hypotension and fainting when combined with flibanserin. The FDA label advises avoiding alcohol close to your bedtime dose and stopping drinking for the evening before taking it. Your clinician reviews this with you in detail.
Reported side effects include dizziness, drowsiness, nausea, fatigue, insomnia, and dry mouth. Many are mild and improve with continued use. Significant lightheadedness or fainting should be reported to your clinician right away.
Flibanserin is FDA-approved for adult premenopausal women with acquired, generalized HSDD. Some clinicians consider it off-label in postmenopausal women on a case-by-case basis. Eligibility is determined during clinician review.
If you have not seen a meaningful improvement by about 8 weeks, the FDA label recommends discontinuing flibanserin. Your care team helps you weigh next steps and whether a different approach may fit better.